There is a great deal of information regarding the minimal requirements for activation of primed T cells. T cell clones can be stimulated to release granule contents and produce lymphokines by anti-CD3 antibody or purified antigen-MHC proteins. T cell hybridomas can also be stimulated to produce lymphokines by anti-CD3 antibody or purified antigen-MHC proteins. Activation of these primed T cell lines can occur in the absence of specialized presenting cells and their accessory molecules. This project is to define the minimal requirements for activation of naive T cells and to evaluate the effects of additional stimuli on the magnitude and type of T cell activation elicited. We have been successful in the activation of T cells using different activators such as: anti-CD3 antibody and purified allo-MHC molecules. The relevant cell populations in the activation are being evaluated by fluorescent activated cell sorting. We are presently studying different T cell activation parameters (lymphokine production, anergy, induction, signal transduction, and gene expression) in this sytem. We will then evaluate changes in these T cell responses caused by the deletion or addition of antigen presenting cells, lymphokines, adhesion molecules or costimulatory molecules to T cell stimulus. We have generated a recombinant soluble immune ICAM-1 for use in our experiments and will pursue the generation of other soluble adhesion/costimulatory molecules. The molecular requirements for T cell activation and the varying phenotypes of this activation are very basic to the generation of successful immunity and the modulation of aberrant immune responses.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BO003006-03
Application #
2569025
Study Section
Special Emphasis Panel (LMDI)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost